Skip to main content
. 2019 Apr 29;145(7):1958–1969. doi: 10.1002/ijc.32325

Figure 1.

Figure 1

DCVacc/VSV‐GP combination therapy showed significant survival benefit compared to single treatments. (a) Tumor growth curves of s.c. B16‐OVA melanoma in C57BL/6 mice treated i.t./p.t. on Days 11, 18 and 25 posttransplantation with PBS, VSV‐GP (6 × 107 PFU), DCVacc (2 × 105 SIINFEKL‐loaded CpG‐matured bmDCs) or DCVacc/VSV‐GP. Number of mice with a complete remission (CR) to the treatment are indicated in the Figures. (b) Overall survival. Data were analyzed by Mantel–Cox test. PBS vs. VSV‐GP = p < 0.0001; PBS vs. DCVacc = p < 0.0001; PBS vs. DCVacc/VSV‐GP = p < 0.0001. DCVacc/VSV‐GP vs. VSV‐GP = p < 0.01 and DCVacc/VSV‐GP vs. DCVacc = p < 0.01. Data represent results from two independent experiments with a total of n = 12–13 mice per group.